Nephrogenic systemic fibrosis: A devastating complication of gadolinium in patients with severe renal impairment

Vascular Disease Management

Volumn 4, Issue 2, 2007, Pages 45-47

  Perazella, Mark A ^a   Rodby, Roger A ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; IMMUNOGLOBULIN; PENTOXIFYLLINE; PSORALEN; SODIUM THIOSULFATE; STEROID;

CLINICAL FEATURE; CONTRAST ENHANCEMENT; DISEASE DURATION; DISEASE SEVERITY; DRUG MEGADOSE; EARLY DIAGNOSIS; GRAFT RECIPIENT; HEPATORENAL SYNDROME; HUMAN; KIDNEY DISEASE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY INJURY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PLASMAPHERESIS; PUVA; RISK ASSESSMENT; SHORT SURVEY;

EID: 33947305581     PISSN: 15538036     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (18)

1. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous disease in renal-dialysis patients. Lancet 2000;356:1000-1001.
2. Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 2006;18:614-617.
3. Cowper SE. Nephrogenic Fibrosing Dermopathy [NFD/NSF Website]. 2001-2006. Available at http://www.icnfdr.org. Accessed 2/9/2007.
4. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-1108.
5. Marckmann P, Skov L, Rossen, et al. Nephrogenic systemic fibrosis: Suspected etiological role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359-2362.
6. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: A population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol (published 7 February 2007, 10.2215/CJN.03921106).
7. Yerram P, Saab G, Karuparthi PR, et al. Nephrogenic systemic fibrosis-A mysterious disease in dialysis patients: Role of gadodiamide in causation and the beneficial effect of IV sodium thiosulfate. Clin J Am Soc Nephrol (published 7 February 2007, 10.2215/CJN.03250906).
8. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned. Am J Radiol 2007;188:1-7.
9. Khurana A, Runge VM, Narayanan M, et al. Nephrogenic systemic fibrosis: A review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 2007;42:139-145.
10. Food and Drug Adminisration (2006) Public Health Advisory: Gadolinium-containing contrast agents for magnetic resonance imaging (MRI). http://www.fda.gov/cder/drug/advisory/gadolinium_agents.htm
11. Food and Drug Adminisration (2006) Public Health Advisory: Gadolinium-containing contrast agents for magnetic resonance imaging (MRI). http://www.fda.gov/cder/drug/advisory/gadolinium_agents_20061222.htm
12. High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2006;56:21-26.
13. Boyd AC, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2006;56:27-30.
14. Swan SK, Lambrecht LJ, Townsend R, et al. Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol 1999;34:443-448.
15. Saitoh T, Hayasaka K, Tanaka Y, et al. Dialyzability of gadodiamide in hemodialysis patients. Radiat Med 2006;24:445-451.
16. Runge VM. Safety of magnetic resonance contrast media. Topics Magn Res Imaging 2001;12:309-314.
17. Perazella MA. Nephrogenic systemic fibrosis, kidney disease, and gadolinium: Is there a link? Clin J Am Soc Nephrol (published 7 February 2007, 10.2215/CJN.00030107).
18. Perazella MA, Rodby RA. Gadolinium use in patients with kidney disease: A cause for concern. Semin Dial (in press).